Patients submitted for consideration for treatment with GS010/Lumevoq must meet specific eligibility criteria, including the length of time since the onset of their vision loss.

D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D ...

News » DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies ...

Studienergebnisse DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies 23.12.2025 / 14:36 CET/CEST ...

This article explores limitations of chemical synthesis in high-throughput settings and the technical advantages enzymatic ...

Francesca Vitelli and Orla Cloak from Minaris with Matthew Durdy, Eytan Abraham, and Dan Gibson of CGT Catapult.

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

Dubai, UAE: The Emirates Drug Establishment (EDE) has announced the approval of Itvisma™ (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular ...

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) ...

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...

As of Friday, December 19, BioMarin Pharmaceutical Inc.’s BMRN share price has surged by 14.13%, which has investors questioning if this is right time to sell.